公开(公告)号：US09751876B2

公开(公告)日：2017-09-05

申请号：US14511044

申请日：2014-10-09

Applicant: Novartis AG

Inventor： Ian Bruce ,  Sylvie Chamoin ,  Stephen Paul Collingwood ,  Pascal Furet ,  Vikki Furminger ,  Diana Janus ,  Sarah Lewis ,  Jon Christopher Loren ,  Valentina Molteni ,  Alex Michael Saunders ,  Duncan Shaw ,  Lilya Sviridenko ,  Christopher Thomson ,  Ryan West ,  Vince Yeh

IPC: C07D471/04 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5377 ,  A61K45/06 ,  A61K31/4745

CPC classification number: C07D471/04 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/5377 ,  A61K45/06

Abstract: Bicyclic heterocyclic derivatives of formula I useful in inhibiting PDGF receptor mediated biological activity. wherein A is and R1, R1a, R2, R3, R4, R5, R6 and X are as defined herein.

公开(公告)号：US09040559B2

公开(公告)日：2015-05-26

申请号：US14450692

申请日：2014-08-04

Applicant: Novartis AG

Inventor： Bernard Cuenoud ,  Ian Bruce ,  Robin Alec Fairhurst ,  David Beattie

IPC: A61K31/395 ,  A61K31/4709 ,  C07C215/80 ,  C07C233/43 ,  C07C311/08 ,  C07D215/227 ,  C07D215/26 ,  C07D405/12 ,  A61K45/06

CPC classification number: A61K31/4709 ,  A61K45/06 ,  C07C215/80 ,  C07C233/43 ,  C07C311/08 ,  C07C2602/08 ,  C07D215/227 ,  C07D215/26 ,  C07D405/12

Abstract: Compounds of formula in free or salt or solvate form, where Ar is a group of formula Y is carbon or nitrogen and R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.

Abstract translation: 其中Ar为式Y的化合物为碳或氮，R1，R2，R3，R4，R5，R6，R7，R8，R9，R10，X，n，p， q和r如说明书中所定义，它们的制备及其作为药物的用途，特别是用于治疗阻塞性或炎症性气道疾病。

公开(公告)号：US20180243297A1

公开(公告)日：2018-08-30

申请号：US15963535

申请日：2018-04-26

Applicant: Novartis AG

Inventor： Benjamin Richard Bellenie ,  Graham Charles Bloomfield ,  Ian Bruce ,  Andrew James Culshaw ,  Edward Charles Hall ,  Gregory John Hollingworth ,  James Neef ,  Matthew Spendiff ,  Simon James Watson

IPC: A61K31/497 ,  C07D413/14 ,  A61K31/5377 ,  C07D405/04 ,  C07D409/14 ,  C07D417/14 ,  C07D401/14 ,  C07D413/04 ,  C07D409/04 ,  C07D403/14 ,  C07D403/04 ,  C07D401/04 ,  C07D405/14 ,  C07D417/04

CPC classification number: A61K31/497 ,  A61K31/5377 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14

Abstract: The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.

公开(公告)号：US20180125849A1

公开(公告)日：2018-05-10

申请号：US15867425

申请日：2018-01-10

Applicant: Novartis AG

Inventor： Graham Charles Bloomfield ,  Ian Bruce ,  Brian Cox ,  Lee Edwards ,  Judy Fox Hayler ,  Catherine Howsham

IPC: A61K31/519 ,  A61K31/5377 ,  C07D487/04

CPC classification number: A61K31/519 ,  A61K31/5377 ,  C07D487/04

Abstract: The present invention concerns a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, where R1-R3 and Y are defined in the description, and its use in the treatment of disorders in which pi3 kinase is implicated.

公开(公告)号：US08901134B2

公开(公告)日：2014-12-02

申请号：US14261890

申请日：2014-04-25

Applicant: Novartis AG

Inventor： Graham Charles Bloomfield ,  Ian Bruce ,  Brian Cox ,  Lee Edwards ,  Judy Fox Hayler ,  Catherine Howsham

IPC: A01N43/90 ,  A61K31/519 ,  C07D487/00 ,  C07D487/04

CPC classification number: A61K31/519 ,  A61K31/5377 ,  C07D487/04

Abstract: The present invention concerns a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, where R1-R3 and Y are defined in the description, and its use in the treatment of disorders in which pi3 kinase is implicated.

Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐或溶剂合物，其中R1-R3和Y在说明书中定义，及其用于治疗其中涉及pi3激酶的病症。